Entities / Company
Apellis Pharmaceuticals (United States).
company in Crestwood, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 38
What's happening
Gone quiet
No new reports in 90+ days-
Apellis Pharmaceuticals secured a royalty purchase agreement with Sobi, while also awaiting FDA regulatory decisions, amid AI stock trends benefiting from tariffs.Speculative2 reports
-
Apellis Pharmaceuticals is leveraging its status as a high-growth company to pursue license agreements with companies like Swedish Orphan Biovitrum AB and Beam Therapeutics, amidst favorable AI market trends.Speculative1 report
-
Both Zai Lab Limited and Apellis Pharmaceuticals are identified as high-growth biopharmaceutical companies.Speculative1 report
-
The ASRS Annual Scientific Meeting was held in Long Beach, involving Apellis Pharmaceuticals.Some support1 report
-
Apellis Pharmaceuticals used LinkedIn and Twitter for professional outreach and social media presence on July 24, 2025.Some support1 report
-
Apellis Pharmaceuticals stock performance outpaced the broader market index on July 31, 2025.Some support1 report
-
Apellis Pharmaceuticals reported that its revenue growth forecast is lower than the industry average.Some support1 report
-
Apellis Pharmaceuticals and Sobi reached a capped royalty purchase agreement following FDA approval of EMPAVELI.Some support5 reports
-
Apellis Pharmaceuticals began using LinkedIn for company presence on August 27, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Apellis Pharmaceuticals (United States) this week
News at the entities that move Apellis Pharmaceuticals (United States) most-
FDA StructuralFDA conducted surprise raids and inspections in Bihar state, directed by state government officials.Moves Apellis Pharmaceuticals (United States)
-
Raymond James Mentioned togetherWesBanco, led by CEO Jeffrey Jackson and CFO Daniel Weiss, is facing scrutiny from major financial analysts regarding its performance, credit trends, and loan growth sustainability.Moves Apellis Pharmaceuticals (United States)
Connections
The 3 strongest of 38, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
sobi Transactional
Sobi acquired 90% of Apellis' ex-U.S. royalties, establishing a financial agreement and joint development rights.
-
FDA Structural
The FDA formally regulates Apellis Pharmaceuticals, granting designations and approving the use of its drugs.
-
Raymond James Mentioned together
Raymond James provides financial analysis and tracks the performance of Apellis Pharmaceuticals.
History
Events by the month they beganJune 2026
9 events- Apellis Pharmaceuticals secured a royalty purchase agreement with Sobi, while also awaiting FDA regulatory decisions, amid AI stock trends benefiting from tariffs.
- Apellis Pharmaceuticals is leveraging its status as a high-growth company to pursue license agreements with companies like Swedish Orphan Biovitrum AB and Beam Therapeutics, amidst favorable AI market trends.
- Both Zai Lab Limited and Apellis Pharmaceuticals are identified as high-growth biopharmaceutical companies.
- The ASRS Annual Scientific Meeting was held in Long Beach, involving Apellis Pharmaceuticals.
- Apellis Pharmaceuticals used LinkedIn and Twitter for professional outreach and social media presence on July 24, 2025.
- Apellis Pharmaceuticals stock performance outpaced the broader market index on July 31, 2025.
- Apellis Pharmaceuticals reported that its revenue growth forecast is lower than the industry average.
- Apellis Pharmaceuticals and Sobi reached a capped royalty purchase agreement following FDA approval of EMPAVELI.
- Apellis Pharmaceuticals began using LinkedIn for company presence on August 27, 2025.